Wedbush maintains BridgeBio Oncology price target at $25.00
Wedbush maintained its BridgeBio Oncology price target at $25.00 per share, according to Benzinga’s ratings action summary.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.